Cost-Effectiveness of 21-Gene Assay in Node-Positive, Early-Stage Breast Cancer
A decision-analytic model was used to estimate cost-effectiveness of adopting a 21-gene assay in treatment decisions for women with early-stage N (1-3)/ER HER2-negative breast cancer.
Ratio of Controller to Total Asthma Medications: Determinants of the Measure
The ratio of controller to total asthma medications can be calculated using 1 or 2 quarters of data; high versus low ratios differentiate patient characteristics.
